Related Experiment Videos
Model systems for cardiotoxic effects of anthracyclines
Antibiotics and Chemotherapy
|January 1, 1978
Summary
Anthracycline antibiotics used in cancer therapy can harm the heart. Researchers screened over 50 new anthracyclines in rats, finding varying cardiotoxic effects not linked to anticancer or blood toxicity.
Area of Science:
- Pharmacology
- Cardiology
- Oncology
Background:
- Anthracycline antibiotics are vital cancer chemotherapeutics but exhibit dose-limiting cardiotoxicity.
- Existing animal models (rabbits, monkeys) for evaluating anthracycline cardiotoxicity are costly.
- Rats offer a viable model for assessing anthracycline cardiotoxicity, despite challenges in visualizing morphologic lesions.
Purpose of the Study:
- To establish and utilize a rat model for screening the cardiotoxic potential of novel anthracycline derivatives.
- To identify structure-activity relationships among anthracycline derivatives concerning cardiotoxicity.
Main Methods:
- Induction of cardiotoxicity in rats using anthracycline antibiotics.
- Monitoring of cardiac function via electrocardiogram (ECG) and cardiac output measurements.
- Assessment of mitochondrial function, including electron transfer, oxidative phosphorylation, and calcium translocation.
- Utilizing intraventricular conduction defects on ECG as a primary screening parameter for cardiotoxicity.
Main Results:
- Anthracycline administration in rats induced dose-dependent morphologic and functional cardiac changes.
- ECG-detected intraventricular conduction defects served as an early and consistent marker of anthracycline cardiotoxicity.
- Screening of over 50 novel anthracyclines revealed significant variability in cardiotoxic properties.
- Cardiotoxicity did not strongly correlate with chemotherapeutic efficacy or hematotoxicity.
- Specific structure-activity relationships were noted within a series of rubidazone derivatives.
Conclusions:
- The rat model effectively screens anthracycline cardiotoxicity, with ECG changes being a reliable indicator.
- Novel anthracycline derivatives exhibit diverse cardiotoxic profiles, independent of their primary therapeutic or hematotoxic effects.
- This research facilitates the development of safer anthracycline-based cancer therapies by identifying less cardiotoxic compounds.